Echinoderm microtubule-associated protein-like 4-anaplastic lymphoma kinase (EML4-ALK) rearrangement, also known as the ALK-positive variant, is one of the significant driver mutations in non-small-cell lung cancer (NSCLC) and accounts for about 5% of NSCLC (1–3). Here, EML4 is linked to non-small cell lung carcinoma.